Artemisinin-based combination therapy for ... - The Cochrane Library

More documents

Recommendations

Info

$Interventions for treating proximal humeral fractures in adults (Review)$

Analysis 1.13. Comparison 1 Dihydroartemisinin-piperaquine vs Artesunate plus mefloquine, Outcome 13 Sensitivity analysis: Total Failure Day 63 PCR adjusted. Review: Artemisinin-based combination therapy for treating uncomplicated malaria Comparison: 1 Dihydroartemisinin-piperaquine vs Artesunate plus mefloquine Outcome: 13 Sensitivity analysis: Total Failure Day 63 PCR adjusted Study or subgroup DHA-P AS+MQ Risk Ratio Weight Risk Ratio 1 Total Failure (P. falciparum) Day 63 PCR adjusted n/N n/N M-H,Random,95% CI M-H,Random,95% CI Ashley 2003b THA 3/131 9/131 31.7 % 0.33 [ 0.09, 1.20 ] Janssens 2003 KHM 4/181 5/190 31.2 % 0.84 [ 0.23, 3.08 ] Ashley 2004 THA 3/292 7/137 29.7 % 0.20 [ 0.05, 0.77 ] Grande 2005 PER 4/211 0/224 7.4 % 9.55 [ 0.52, 176.35 ] Subtotal (95% CI) 815 682 100.0 % 0.57 [ 0.17, 1.83 ] Total events: 14 (DHA-P), 21 (AS+MQ) Heterogeneity: Tau 2 = 0.78; Chi 2 = 6.94, df = 3 (P = 0.07); I 2 =57% Test for overall effect: Z = 0.95 (P = 0.34) 2 Total Failure Day 63 PCR adjusted (indeterminate PCR included as failures) Ashley 2003b THA 7/135 10/132 36.1 % 0.68 [ 0.27, 1.74 ] Janssens 2003 KHM 4/181 6/191 23.7 % 0.70 [ 0.20, 2.45 ] Ashley 2004 THA 6/295 8/138 31.2 % 0.35 [ 0.12, 0.99 ] Grande 2005 PER 4/211 1/225 9.0 % 4.27 [ 0.48, 37.86 ] Subtotal (95% CI) 822 686 100.0 % 0.67 [ 0.32, 1.39 ] Total events: 21 (DHA-P), 25 (AS+MQ) Heterogeneity: Tau 2 = 0.17; Chi 2 = 4.28, df = 3 (P = 0.23); I 2 =30% Test for overall effect: Z = 1.08 (P = 0.28) 3 Total Failure Day 63 PCR adjusted (new infections included as successes) Ashley 2003b THA 7/154 10/151 36.0 % 0.69 [ 0.27, 1.76 ] Janssens 2003 KHM 4/195 6/207 23.7 % 0.71 [ 0.20, 2.47 ] Ashley 2004 THA 6/318 8/157 31.2 % 0.37 [ 0.13, 1.05 ] Grande 2005 PER 4/219 1/226 9.1 % 4.13 [ 0.47, 36.64 ] Subtotal (95% CI) 886 741 100.0 % 0.67 [ 0.34, 1.35 ] Total events: 21 (DHA-P), 25 (AS+MQ) Heterogeneity: Tau 2 = 0.12; Chi 2 = 3.96, df = 3 (P = 0.27); I 2 =24% Test for overall effect: Z = 1.11 (P = 0.27) 4 Total Failure Day 63 PCR adjusted (losses to follow up included as failures) Ashley 2003b THA 32/179 35/176 27.8 % 0.90 [ 0.58, 1.38 ] Janssens 2003 KHM 24/215 29/230 24.9 % 0.89 [ 0.53, 1.47 ] 0.001 0.01 0.1 1 10 100 1000 Favours DHA-P Favours AS+MQ Artemisinin-based combination therapy for treating uncomplicated malaria (Review) Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. (Continued ...) 134
(... Continued) Study or subgroup DHA-P AS+MQ Risk Ratio Weight Risk Ratio n/N n/N M-H,Random,95% CI M-H,Random,95% CI Ashley 2004 THA 20/332 17/166 21.0 % 0.59 [ 0.32, 1.09 ] Grande 2005 PER 37/252 26/251 26.3 % 1.42 [ 0.89, 2.27 ] Subtotal (95% CI) 978 823 100.0 % 0.93 [ 0.67, 1.30 ] Total events: 113 (DHA-P), 107 (AS+MQ) Heterogeneity: Tau 2 = 0.05; Chi 2 = 5.22, df = 3 (P = 0.16); I 2 =43% Test for overall effect: Z = 0.41 (P = 0.68) 5 Total Failure Day 63 PCR adjusted (losses to follow up included as successes) Ashley 2003b THA 7/179 10/176 35.9 % 0.69 [ 0.27, 1.77 ] Janssens 2003 KHM 4/215 6/230 23.7 % 0.71 [ 0.20, 2.49 ] Ashley 2004 THA 6/332 8/166 31.3 % 0.38 [ 0.13, 1.06 ] Grande 2005 PER 4/252 1/251 9.1 % 3.98 [ 0.45, 35.40 ] Subtotal (95% CI) 978 823 100.0 % 0.67 [ 0.34, 1.33 ] Total events: 21 (DHA-P), 25 (AS+MQ) Heterogeneity: Tau 2 = 0.10; Chi 2 = 3.80, df = 3 (P = 0.28); I 2 =21% Test for overall effect: Z = 1.14 (P = 0.25) 0.001 0.01 0.1 1 10 100 1000 Favours DHA-P Favours AS+MQ Artemisinin-based combination therapy for treating uncomplicated malaria (Review) Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. 135
Page 1 and 2:
Artemisinin-based combination thera
Page 3 and 4:
Analysis 2.2. Comparison 2 Dihydroa
Page 5 and 6:
Analysis 10.5. Comparison 10 Arteme
Page 7 and 8:
[Intervention Review] Artemisinin-b
Page 9 and 10:
B A C K G R O U N D Malaria is a di
Page 11 and 12:
drugs and the treatment comparisons
Page 13 and 14:
this analysis into participants who
Page 15 and 16:
Figure 1. Methodological quality su
Page 17 and 18:
confidence intervals of the estimat
Page 19 and 20:
Anaemia Hasugian 2005 IDN found tha
Page 21 and 22:
Three trials report significantly m
Page 23 and 24:
or those treated for P. vivax at ba
Page 25 and 26:
Early vomiting Not reported. D I S
Page 27 and 28:
Figure 4. Olliaro-Vaillant plot. Da
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Figure 10. Olliaro-Vaillant plot. D
Page 35 and 36:
of findings tables’. For these ta
Page 37 and 38:
Huambo and Bie provinces, central A
Page 39 and 40:
References to studies excluded from
Page 41 and 42:
Adjuik 2004 Adjuik M, Babiker A, Ga
Page 43 and 44:
C H A R A C T E R I S T I C S O F S
Page 45 and 46:
Ashley 2003a THA (Continued) Outcom
Page 47 and 48:
Ashley 2003b THA (Continued) Alloca
Page 49 and 50:
Ashley 2005 THA (Continued) Exclusi
Page 51 and 52:
Bonnet 2004 GIN (Continued) Item Au
Page 53 and 54:
Bukirwa 2005 UGA Methods Trial desi
Page 55 and 56:
Djimde 2004 MLI (Continued) • AS
Page 57 and 58:
Dorsey 2006 UGA (Continued) Item Au
Page 59 and 60:
Fanello 2004 RWA Methods Trial desi
Page 61 and 62:
Faye 2003 SEN (Continued) Outcomes
Page 63 and 64:
Grande 2005 PER (Continued) Allocat
Page 65 and 66:
Guthmann 2004 AGO (Continued) All d
Page 67 and 68:
Hasugian 2005 IDN Methods Trial des
Page 69 and 70:
Hutagalung 2002 THA (Continued) 5.
Page 71 and 72:
Janssens 2003 KHM (Continued) Free
Page 73 and 74:
Karema 2004 RWA (Continued) Interve
Page 75 and 76:
Karunajeewa 2007 PNG (Continued) Ri
Page 77 and 78:
Kobbe 2007 GHA (Continued) Exclusio
Page 79 and 80:
Koram 2003 GHA (Continued) Adequate
Page 81 and 82:
Martensson 2003 TZA Methods Trial d
Page 83 and 84:
Mayxay 2003 LAO (Continued) 1. Feve
Page 85 and 86:
Menard 2006 MDG Methods Trial desig
Page 87 and 88:
Mens 2007 KEN (Continued) Risk of b
Page 89 and 90: Mutabingwa 2004 TZA (Continued) •
Page 91 and 92: Owusu-Agyei 2006 GHA (Continued) Fr
Page 93 and 94: Sagara 2005b MLI (Continued) • 25
Page 95 and 96: Smithuis 2004 MMR (Continued) Risk
Page 97 and 98: Stohrer 2003 LAO Methods Trial desi
Page 99 and 100: Swarthout 2004 ZAR (Continued) Note
Page 101 and 102: Tran 2002 VNM Methods Trial design:
Page 103 and 104: Van den Broek 2003a BGD (Continued)
Page 105 and 106: Van Vugt 1998 THA Methods Trial des
Page 107 and 108: Yeka 2004 UGA (Continued) Risk of b
Page 109 and 110: Yeka 2007 UGA (Continued) Free of o
Page 111 and 112: Zongo 2007 BFA (Continued) Novartis
Page 113 and 114: (Continued) Fofana 2005 Conference
Page 115 and 116: D A T A A N D A N A L Y S E S Compa
Page 117 and 118: 2.2 Asia 1 317 Risk Ratio (M-H, Fix
Page 119 and 120: Comparison 5. Dihydroartemisinin-pi
Page 121 and 122: Comparison 8. Artesunate plus meflo
Page 123 and 124: Comparison 10. Artemether-lumefantr
Page 125 and 126: Comparison 12. Artesunate plus amod
Page 127 and 128: 5.2 DHA-P 3 doses 3 1116 Risk Ratio
Page 129 and 130: Comparison 21. How does Artesunate
Page 131 and 132: Analysis 1.3. Comparison 1 Dihydroa
Page 137 and 138: (... Continued) Study or subgroup D
Page 139: Analysis 1.12. Comparison 1 Dihydro
Page 163 and 164: (... Continued) Study or subgroup A
Page 165 and 166: Analysis 6.6. Comparison 6 Artesuna
Page 173 and 174: Analysis 9.2. Comparison 9 Artemeth
Page 177 and 178: Analysis 9.8. Comparison 9 Artemeth
Page 183 and 184: Analysis 10.2. Comparison 10 Arteme
Page 191 and 192:
Page 193 and 194:
(... Continued) Study or subgroup A
Page 195 and 196:
Page 197 and 198:
Analysis 12.2. Comparison 12 Artesu
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Analysis 14.2. Comparison 14 Dihydr
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
Page 217 and 218:
(... Continued) Study or subgroup D
Page 219 and 220:
Analysis 20.1. Comparison 20 How do
Page 221 and 222:
Analysis 21.1. Comparison 21 How do
Page 223 and 224:
(Continued) 2. How does artesunate
Page 225 and 226:
(Continued) Sensitivity analysis 1
Page 227 and 228:
(Continued) Smithuis 2004 MMR (652
Page 229 and 230:
Dihydroartemisinin-piperaquine vs A
Page 231 and 232:
(Continued) Mayxay 2003 LAO (220 pa
Page 233 and 234:
Artesunate plus mefloquine vs Amodi
Page 235 and 236:
(Continued) Faye 2003 SEN (509 part
Page 237 and 238:
Artemether-lumefantrine vs Artesuna
Page 239 and 240:
(Continued) Zongo 2005 BFA (521 par
Page 241 and 242:
(Continued) Faye 2003 SEN (521 part
Page 243 and 244:
PCR = polymerase chain reaction PCV
Page 245 and 246:
(Continued) Proportion with anaemia
Page 247 and 248:
(Continued) Vivax efficacy: P. viva
Page 249 and 250:
(Continued) Efficacy: Total Failure
Page 251 and 252:
(Continued) Outcomes Illustrative c
Page 253 and 254:
Page 255 and 256:
(Continued) GRADE Working Group gra
Page 257 and 258:
Footnotes 1 Data were also availabl
Page 259 and 260:
8 Very serious imprecision: There w
Page 261 and 262:
Page 263 and 264:
(Continued) justed Vivax efficacy:
Page 265 and 266:
(Continued) Harms: Serious adverse
Page 267 and 268:
(Continued) Harms: Early vomiting -
Page 269 and 270:
1 Dorsey 2006 UGA; Faye 2003 SEN; K
show all

Artemisinin-based combination therapy for ... - The Cochrane Library

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?